Targeted therapy in breast cancer: the HER-2/neu gene and protein (Q35648508)

9 August 2017

1 reference

title

Targeted therapy in breast cancer: the HER-2/neu gene and protein (English)

1 reference

9 August 2017

1 reference

8

Gabriel N Hortobagyi

1 reference

9 August 2017

Jeffrey S Ross

1

1 reference

9 August 2017

Jonathan A Fletcher

2

1 reference

9 August 2017

Kenneth J Bloom

3

1 reference

9 August 2017

Gerald P Linette

4

1 reference

9 August 2017

James Stec

5

1 reference

9 August 2017

W Fraser Symmans

6

1 reference

9 August 2017

Lajos Pusztai

7

1 reference

9 August 2017

language of work or name

1 reference

3 February 2004

1 reference

Molecular & Cellular Proteomics

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

4

1 reference

9 August 2017

379-398

1 reference

Untangling the ErbB signalling network

9 August 2017

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

A decade of tyrosine kinases: from gene discovery to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Expression of C-erbB-2 Oncoprotein in Mammary and Extramammary Paget's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Molecular markers in Paget disease of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Molecular markers in male breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Status of HER-2 in male and female breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

c-erbB-2 in breast cancer: development of a clinically useful marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic and predictive value of HER2/neu oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The predictive value of HER2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The long term prognostic significance of c-erbB-2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic significance of c-erbB-2 expression in node negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

FISH detection of HER-2/neu oncogene amplification in early onset breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

C-erbB-2 overexpression and survival in early onset breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The association of HER-2/neu amplification with breast cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic value of c-erbB2 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Current status of HER2 testing: caught between a rock and a hard place

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Validation of tissue microarray technology in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Improved procedure for fluorescence in situ hybridization on tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Role of adjuvant endocrine therapy in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Prediction of response to hormonal treatment in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R400001-MCP200

10.1074/MCP.R400001-MCP200

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference